| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 08/03/2005 | CN1649611A Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
| 08/03/2005 | CN1649609A Soybean saponin-containing material and process for producing the same |
| 08/03/2005 | CN1649607A A process for the extraction of anthocyanins from black rice and composition thereof |
| 08/03/2005 | CN1649601A Difructose anhydride-containing composition and use thereof |
| 08/03/2005 | CN1649595A Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy |
| 08/03/2005 | CN1649593A Use of 2-alkoxyphenyl-substituted imidazotriazinones |
| 08/03/2005 | CN1649586A Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
| 08/03/2005 | CN1649582A Amino-methyl substituted tetracycline compounds |
| 08/03/2005 | CN1649581A Substituted 3-amino-thieno(2, 3-b)pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses |
| 08/03/2005 | CN1649580A Pharmaceutical composition comprising a lipase inhibitor and glucomannan |
| 08/03/2005 | CN1649577A Preventing and/or treating cardiovascular disease and/or associated heart failure |
| 08/03/2005 | CN1649574A Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies |
| 08/03/2005 | CN1649517A Soft drink replacer |
| 08/03/2005 | CN1647827A Method and device for the treatment of obesity |
| 08/03/2005 | CN1647675A Natural liver protection and fat clearing product |
| 08/03/2005 | CN1213044C Amine and amide derivatives as ligands for neuropeptide YY5 receptor useful in treatment of obesity and other disorders |
| 08/03/2005 | CN1213033C Crystalline bis [(E)-7[4-(4-(4-fluorophenyl)-6-isopropy-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl] (3R,5S-3,5-dihydroxyhept-6-enoic acid] calcium salt |
| 08/03/2005 | CN1213028C Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl IV, processes for their preparation, and their use |
| 08/03/2005 | CN1213017C Propynyl or diene diaryl compounds |
| 08/03/2005 | CN1212831C Pharmaceutical preparations |
| 08/03/2005 | CN1212830C Delivery of solid drug compositions |
| 08/02/2005 | US6924374 Modulators of dopamine neurotransmission |
| 08/02/2005 | US6924314 Compounds for the treatment of metabolic disorders |
| 08/02/2005 | US6924309 Modulation cystic fibrosis; antiinflammatory agents; antiallergens; rheumatic diseases; autoimmune diseases |
| 08/02/2005 | US6924300 Oxyiminoalkanoic acid derivatives |
| 08/02/2005 | US6924297 Naphathalene derivatives which bind to the EP4 receptor |
| 08/02/2005 | US6924295 Hetereocyclic amines such as 3-(5-(2-(2-(4-methylphenyl)-5-methyloxazol-4-yl)ethoxy)-1,2,3,4-tetrahydroquinolin-1-yl)propanoic acid ethyl ester, used as peroxisome proliferator activated receptor modulators; hyperlipemia; diabetis; |
| 08/02/2005 | US6924292 Nitrogen compounds such as 2-(methylsulfinyl) N [3-(3,4,8,9-tetrahydro-6-methoxy-3,3,8,8-tetramethylfuro[2,3-h]isoquinolin-1-yl)phenyl]acetamide, used as phosphodiesterase inhibitors; antidiabetics; antiinflammatory agents |
| 08/02/2005 | US6924289 Useful for treating or preventing a disorder or condition selected from hypertension, depression, anxiety, phobias, post trauma stress, sexual disfunction, eating disorder, obesity, Alzheimer's disease, Parkinson's disease etc. |
| 08/02/2005 | US6924281 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| 08/02/2005 | US6924280 Dipeptide derivatives |
| 08/02/2005 | US6924277 Central nervous system disorders; antidepressants; bipolar disorders; rhematic diseases |
| 08/02/2005 | US6924266 NTP-peptides and method for removal of tumors |
| 08/02/2005 | US6924100 Nucleotide sequences coding preferential polypeptide for use in the treatment and diagnosis of cardiovascular disorders and headaches |
| 08/02/2005 | US6923988 Solid carrier includes a hydrophililc surfactant and a drug |
| 08/02/2005 | US6923959 Method of pre-inducing a state of immune tolerance before organ transplantation |
| 08/02/2005 | CA2325358C 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b |
| 08/02/2005 | CA2304821C Osteoblast-specific mitogens and drugs containing such compounds |
| 07/30/2005 | CA2456593A1 Peptides for the diagnosis, monitoring and treatment of diabetes |
| 07/29/2005 | CA2455248A1 Oral administration of r-albuterol against obesity |
| 07/28/2005 | WO2005068467A1 Novel fused-ring compound |
| 07/28/2005 | WO2005067952A1 Formulation for treating obesity and associated metabolic syndrome |
| 07/28/2005 | WO2005067913A1 Lipase inhibitor |
| 07/28/2005 | WO2005067904A1 Abca1 stabilizer |
| 07/28/2005 | WO2005033102A3 Thiophene-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| 07/28/2005 | WO2005020983A3 Combination therapy for glycaemic control |
| 07/28/2005 | WO2003072035A8 Compositions and methods for the treatment of immune related diseases |
| 07/28/2005 | WO2002096905A8 Thiazole compounds useful as inhibitors of protein kinases |
| 07/28/2005 | WO2002055010A3 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration |
| 07/28/2005 | US20050165242 hydrolysis of atorvastatin lactone with sodium hydroxide to form atorvastatin sodium salt solution; addition to an aqueous calcium chloride or calcium acetate solution; andisolation by filtration and drying; scalable, cost-effective and robust process |
| 07/28/2005 | US20050165240 Chemical intermediates for production of sibutramine |
| 07/28/2005 | US20050165108 reacting D-phenylalanine methylester HCl with trans-4-isopropylcyclohexane carboxylic acid in presence of propane phosphonic acid anhydride or LiOH Al2O3 in a halogenated hydrocarbon solvent such as dichloromethane or dichloroethane; type 2 diabetes mellitus |
| 07/28/2005 | US20050165106 Preferentially inhibit the inducible isoform of nitric oxide synthase |
| 07/28/2005 | US20050165103 for enhancing the endogenous production of interleukin-10 (IL-10) and suppressing the production of interleukin-2 in mammalian cells or tissues; inhibiting the proliferation of stimulated peripheral mononuclear cells |
| 07/28/2005 | US20050165100 Conjugated fatty acid esters |
| 07/28/2005 | US20050165091 includes a buffering agent to stabilize and maintain the pH below 9 in an aqueous dispersion; slow the degradation; shelf-life |
| 07/28/2005 | US20050165087 Nf-kb inhibitors |
| 07/28/2005 | US20050165086 Aminothiophene inhibitors of NF- kappa B inhibitors for treatment of diseases such as cancer or aids |
| 07/28/2005 | US20050165084 Nitrate derivatives of atorvastatin with improved pharmacological activity and enhanced tolerability; treating coronary syndromes, neurodegenerative disorders, and for reducing cholesterol levels; antiinflammatory, antithrombotic and antiplatelet activity; atorvastatin 4-(nitrooxy)butyl ester |
| 07/28/2005 | US20050165057 cholesterol acyl transferase inhibitor for treatment of hyperlipidemia and atherosclerosis; piperidin-4-yl]methyl urea derivatives |
| 07/28/2005 | US20050165045 Compounds and methods |
| 07/28/2005 | US20050165039 Fluorinated 4-azasteroid derivatives as androgen receptor modulators |
| 07/28/2005 | US20050165036 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists |
| 07/28/2005 | US20050165022 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses |
| 07/28/2005 | US20050165019 Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same |
| 07/28/2005 | US20050165017 Such as (3S)-2-[3-[(phenylacetyl)amino]-1-oxopropyl]-N-[cyano(3-phenoxyphenyl)methyl]hexahydro-3-pyridazinecarboxamide; for treatment of osteoporosis, hypercalcaemia, osteoporosis, gingival disease, arthritis, Paget's disease, and bone cancer |
| 07/28/2005 | US20050165016 Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase |
| 07/28/2005 | US20050165011 6-[5-(6-methyl-pyridin-2-yl)-1H-[1,2,3]triazol-4-yl]-4H-benzo[1,4]oxazin-3-one, used as inhibitors of the transforming growth factor beta-signalling pathways, in particular, the phosphorylation of smad gene and proteins or activin-like kinase receptors; prophylaxis of kidney fibrosis |
| 07/28/2005 | US20050164995 Method of locking 1alpha-OH of vitamin D compounds in axial orientation |
| 07/28/2005 | US20050164989 Novel $g(a)-amino-n-(diaminophosphinyl) lactam derivative |
| 07/28/2005 | US20050164988 Bisphosphate, bis-quaternary ammonium or bis-amine salt compounds that bind a Toll-like receptor; use desensitizing allergies, treating autoimmune diseases and inflammatory diseases, ischemia |
| 07/28/2005 | US20050164926 Novel recombinant anticoagulant proteins |
| 07/28/2005 | US20050164925 Treatment of gastroparesis |
| 07/28/2005 | US20050164342 Cloned glutamic acid decarboxylase |
| 07/28/2005 | US20050164337 Using metal affinity chromatography to isolate beta -conglycinin-enriched soluble protein fraction for use in treatment of hyperlipidemias; anticholesterol agents |
| 07/28/2005 | US20050164233 Compositions, kits and methods for identification and modulation of type I diabetes |
| 07/28/2005 | US20050164185 Interferon receptor variant for treatment and prevention of cell proliferative, autoimmune and viral diseases; prolonged activation of interferon beta |
| 07/28/2005 | US20050164183 Adipocyte differentiation-associated gene and protein |
| 07/28/2005 | US20050163864 Comprises vitamin C, vitamin E, vitamin A (beta-carotene), zinc oxide, and cupric oxide; for promotion of retinal health |
| 07/28/2005 | US20050163863 use of arsenic for treating autoimmune diseases, in particular autoimmune lymphoproliferative syndrome |
| 07/28/2005 | US20050163778 Extracorporeal photopheresis in combination with anti-TNF treatment |
| 07/28/2005 | US20050163744 Novel method for down-regulation of amyloid |
| 07/28/2005 | US20050163728 A mixture of polypeptides, as calcium binding protein for reducing bone loss and reducing renal phosphate excretion; biodrug for treating bone disorders; injectable solution or dispersed in toothpaste or a mouthwash or gum patch |
| 07/28/2005 | US20050163727 Topical, oral administration; mouthrinses; microbiocides; bactericides; prevents spread of pathogenic oral bacteria, toxins and endotoxins, and resultant inflammatory cytokines and mediators; cardiovascular disease, stroke, atherosclerosis |
| 07/28/2005 | US20050163723 Synthesis of small particles |
| 07/28/2005 | DE10360924A1 Composition containing metformin, useful as antidiabetic, is formulated as water-soluble granules for administration, after dissolution, through a gastric tube |
| 07/28/2005 | CA2584191A1 Formulation for treating obesity and associated metabolic syndrome |
| 07/28/2005 | CA2553988A1 Pharmaceutical compositions comprising higher primary aliphatic alcohols and hmg coa reductase inhibitor and process of preparation thereof |
| 07/28/2005 | CA2553985A1 Pharmaceutical compositions comprising higher primary alcohols and ezetimibe and process of preparation thereof |
| 07/28/2005 | CA2553774A1 Novel compositions comprising higher primary alcohols and nicotinic acid and process of preparation thereof |
| 07/28/2005 | CA2553710A1 Abca1 stabilizer |
| 07/28/2005 | CA2553594A1 Particle-induced ghrelin immune response |
| 07/28/2005 | CA2553329A1 New fused polycyclic compounds |
| 07/28/2005 | CA2553202A1 Tricyclic benzazepine derivatives as squalene synthase inhibitors used for the treatment of cardiovascular diseases |
| 07/28/2005 | CA2552965A1 Carboxamide derivative and use thereof |
| 07/28/2005 | CA2552550A1 Piperidine derivatives as gcs inhibitors |
| 07/28/2005 | CA2552471A1 Combination of crf antagonists and 5-ht 1b receptor antagonists |
| 07/28/2005 | CA2551639A1 (3-oxo-3, 4-dihydro-quinoxalin-2-yl-amino) -benzamide derivatives and related compound as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity |
| 07/28/2005 | CA2551119A1 Lipase inhibitor |
| 07/28/2005 | CA2456430A1 Improved process for the preparation of amorphous atorvastatin calcium |